BRIGHT MINDS BIOSCIENCES Clinical Trials

Company details

Status: Public
HQ: 19 Vestry St, New York, NY 10013, US
Employees: 12
Programs: 1063
Drugs: 444
Patents: 57

Official website ↗ All projects Drug pipeline Patents News & analysis

Recent trial activity

8 updates

Latest clinical program signals indexed for BRIGHT MINDS BIOSCIENCES.

Trial registry

580 studies

NCT00000187
Ritanserin

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000188
Selegiline

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000189
Gepirone

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000193
Gamma hydroxybutyric

Phase 2 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000194
Cycloserine

Phase 2 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000200
Methadone

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000201
Selegiline

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000211
Buprenorphine

Phase 3 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000212
Desipramine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000214
Buprenorphine

Phase 3 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000216
Buprenorphine

Phase 3 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000240
Buprenorphine

Phase 3 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000241
Flupenthixol

Phase 2 completed small_molecule

Substance-Related Disorders

CT.gov ↗
NCT00000244
Dynorphin 1 - 13

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000245
Desipramine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000246
Flumazenil

Phase 2 completed small_molecule

Substance-Related Disorders

CT.gov ↗
NCT00000248
Pergolide

Phase 3 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000249
20% N2O

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000250
0% N2O

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000252
0% N2O

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000255
Nitrous oxide

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000261
30% Nitrous oxide

Phase 2 completed small_molecule

Alcohol-Related Disorders

CT.gov ↗
NCT00000267
Risperidone

Phase 2 terminated small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000271
Desipramine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000274
Flupenthixol

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000277
Mazindol

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000278
Disulfiram

Phase 2 completed small_molecule

Alcohol-Related Disorders

CT.gov ↗
NCT00000279
Clonidine

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000282
Pemoline

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000286
Nefazodone

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000288
Cotinine fumarate

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00000291
Labetalol

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000294
Carvedilol

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000295
Micronized Progesterone

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00000296
Cotinine fumarate

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00000302
Buprenorphine

Phase 3 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00000303
Baclofen

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000304
Dextroamphetamine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000305
Dextroamphetamine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000306
Dextroamphetamine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000307
Naltrexone

Phase 2 completed small_molecule

Alcohol-Related Disorders

CT.gov ↗
NCT00000308
Dextroamphetamine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000309
Risperidone

Phase 2 terminated small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000310
Risperidone

Phase 2 terminated small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000311
Buprenorphine

Phase 3 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000312
M-CPP

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000314
M-CPP

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000317
Risperidone

Phase 2 terminated small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000322
Tyrosine

Phase 2 completed other

Amphetamine-Related Disorders

CT.gov ↗
NCT00000326
Heroin Dependence

Phase 2 terminated small_molecule

Heroin Dependence

CT.gov ↗
NCT00000328
Opioid-Related Disorders

Phase 2 terminated small_molecule

Heroin Dependence

CT.gov ↗
NCT00000329
Opioid-Related Disorders

Phase 2 terminated small_molecule

Heroin Dependence

CT.gov ↗
NCT00000330
Opioid-Related Disorders

Phase 2 terminated small_molecule

Heroin Dependence

CT.gov ↗
NCT00000331
Test Drug

Phase 2 terminated small_molecule

Heroin Dependence

CT.gov ↗
NCT00000332
Nimodipine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000336
Selegiline

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000340
Pemoline

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000342
Risperidone

Phase 2 terminated small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000344
Buprenorphine/naloxone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000347
Risperidone

Phase 2 terminated small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00000354
Lofexidine

Phase 3 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00000356
LAAM

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00004373
alprazolam

Phase 2 completed small_molecule

Anxiety Disorder

CT.gov ↗
NCT00015028
Buprenorphine/naloxone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00015106
Lamotrigine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00015132
Sertraline

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00015288
Buprenorphine/naloxone

Phase 3 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00021671
Erythromycin

Phase 3 completed small_molecule

HIV Infections

CT.gov ↗
NCT00023283
Buprenorphine

Phase 3 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00032942
Lofexidine

Phase 3 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00032955
Buprenorphine/naloxone

Phase 3 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00032981
Behavior Therapy

Phase 3 completed other

Substance-Related Disorders

CT.gov ↗
NCT00033007
Behavior Therapy

Phase 3 completed other

Substance-Related Disorders

CT.gov ↗
NCT00033033
Reserpine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00033046
Modafinil

Phase 2 active small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00038688
Peer HIV Education Program

Phase 3 completed other

HIV Infections

CT.gov ↗
NCT00040040
Bupropion

Phase 2 active small_molecule

Amphetamine-Related Disorders

CT.gov ↗
NCT00040053
Ondansetron

Phase 2 completed small_molecule

Amphetamine-Related Disorders

CT.gov ↗
NCT00060814
Combined intervention

Phase 2 completed other

Tobacco Use Disorder

CT.gov ↗
NCT00067158
nicotine transdermal system

Phase 3 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00069251
Bupropion

Phase 2 active small_molecule

Amphetamine-Related Disorders

CT.gov ↗
NCT00074425
BufferGel

Phase 2 completed small_molecule

HIV Infections

CT.gov ↗
NCT00076232
Acyclovir

Phase 3 completed small_molecule

HIV Infections

CT.gov ↗
NCT00078130
Buprenorphine/naloxone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00084175
Behavior Therapy

Phase 3 completed other

Behavior Therapy

CT.gov ↗
NCT00086255
Tiagabine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00086385
Nicotine polacrilex, Bupropion

Phase 3 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00086411
nicotine transdermal system

Phase 3 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00087880
Bupropion and NRT

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00095303
Brief Strategic Family Therapy (BSFT)

Phase 3 completed other

Substance Abuse

CT.gov ↗
NCT00100100
Modafinil

Phase 2 active small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00102362
Behavior Therapy

Phase 3 completed other

Substance-Related Disorders

CT.gov ↗
NCT00104598
Bupropion

Phase 3 active small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00107042
Recombivax

Phase 2 completed mab

Hepatitis B

CT.gov ↗
NCT00110630
10-week smoking cessation group therapy combined with NicoDerm CQ

Phase 3 completed other

Tobacco Use Cessation

CT.gov ↗
NCT00111501
Tobacco Use Disorder

Phase 3 completed other

Tobacco Use Disorder

CT.gov ↗
NCT00111943
1% tenofovir gel

Phase 2 completed small_molecule

HIV Infections

CT.gov ↗
NCT00123578
Lorazepam

Phase 2 terminated small_molecule

Substance-Related Disorders

CT.gov ↗
NCT00128466
gentamicin

Phase 3 completed small_molecule

Plague

CT.gov ↗
NCT00129285
Low Dose Modafinil

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00129311
Selegiline

Phase 2 completed small_molecule

Tobacco Use Cessation

CT.gov ↗
NCT00131456
Venlafaxine

Phase 2 completed small_molecule

Depression

CT.gov ↗
NCT00134875
Buprenorphine/naloxone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00134888
Buprenorphine/naloxone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00134901
Memantine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00135759
Naltrexone

Phase 2 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00135785
Bupropion

Phase 2 completed small_molecule

Methamphetamine

CT.gov ↗
NCT00136760
Bupropion

Phase 2 completed small_molecule

Schizophrenia and Disorders With Psychotic Features

CT.gov ↗
NCT00142727
Methadone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00142818
Naltrexone

Phase 2 completed small_molecule

Alcohol-Related Disorders

CT.gov ↗
NCT00142844
Naltrexone

Phase 2 completed small_molecule

Alcohol-Related Disorders

CT.gov ↗
NCT00142870
Bupropion

Phase 2 completed small_molecule

Marijuana Abuse

CT.gov ↗
NCT00142896
Tramadol

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00142909
Lofexidine

Phase 3 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00142948
Naltrexone

Phase 2 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00144417
CDC-NCHSTP-4448

Phase 2 completed small_molecule

Tuberculosis

CT.gov ↗
NCT00149539
Buprenorphine/naloxone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00149630
Disulfiram

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00149643
Fluoxetine

Phase 2 completed small_molecule

Depressive Disorder, Major

CT.gov ↗
NCT00158132
Propranolol

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00158158
Usual Care

Phase 3 completed small_molecule

Smoking Cessation

CT.gov ↗
NCT00158288
LAAM

Phase 2 completed other

Behavior Therapy

CT.gov ↗
NCT00217932
Divalproex Sodium (Depakote)

Phase 2 completed small_molecule

Mood Disorders

CT.gov ↗
NCT00218036
Modafinil 200mg

Phase 2 terminated small_molecule

Cocaine Abuse

CT.gov ↗
NCT00218062
D-Amphetamine 30mg

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00218114
Divalproex Sodium

Phase 3 completed small_molecule

Attention Deficit and Disruptive Behavior Disorders

CT.gov ↗
NCT00218192
Behavior Therapy

Phase 3 completed other

HCV Negative Status

CT.gov ↗
NCT00218270
Tobacco free snuff

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00218335
Intervention Condition

Phase 2 completed other

HIV

CT.gov ↗
NCT00218348
Dextro-Amphetamine Sulfate

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00218387
Modafinil

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00218413
NicVAX

Phase 2 completed mab

Smoking Cessation

CT.gov ↗
NCT00218426
naltrexone implant

Phase 3 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00218465
GW468816

Phase 2 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT00218491
N-Acetylcysteine

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00218517
Selegiline hydrochloride

Phase 2 completed small_molecule

Marijuana Abuse

CT.gov ↗
NCT00218543
Atomoxetine

Phase 2 completed small_molecule

Attention Deficit Disorder With Hyperactivity

CT.gov ↗
NCT00218569
Naltrexone

Phase 2 completed small_molecule

Alcohol Dependence

CT.gov ↗
NCT00218582
Double Trouble in Recovery

Phase 2 completed other

Dual Diagnosis

CT.gov ↗
NCT00218660
Naltrexone

Phase 3 completed small_molecule

Alcoholism

CT.gov ↗
NCT00223626
Topiramate

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00227812
Bupropion

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00227825
Motivational interviewing

Phase 2 active other

Adherence

CT.gov ↗
NCT00227864
Behavior Therapy

Phase 3 completed other

Marijuana Abuse

CT.gov ↗
NCT00227890
MI/CBT

Phase 2 completed other

Alcoholic, Marijuana Misuse

CT.gov ↗
NCT00227903
MI-CBT

Phase 2 completed other

Alcohol Abuse

CT.gov ↗
NCT00230009
Brief motivational intervention

Phase 2 completed other

Substance Use

CT.gov ↗
NCT00230048
Brief computer-delivered intervention

Phase 2 completed other

Substance-Related Disorders

CT.gov ↗
NCT00235729
Lofexidine

Phase 3 completed small_molecule

Opiate Addiction

CT.gov ↗
NCT00238914
Naltrexone

Phase 2 completed small_molecule

Heroin Dependence

CT.gov ↗
NCT00240110
Valproate

Phase 2 completed small_molecule

Bipolar Disorder

CT.gov ↗
NCT00249431
Sertraline

Phase 2 terminated small_molecule

Alcoholism

CT.gov ↗
NCT00249444
Mirtazapine

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00249483
Venlafaxine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00249561
Recovery by Choice

Phase 2 completed other

Substance-Related Disorders

CT.gov ↗
NCT00249678
Behavior Therapy

Phase 2 terminated other

The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

CT.gov ↗
NCT00249691
Topiramate + Cognitive Behavioral Therapy

Phase 3 active small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT00253890
Trazodone

Phase 3 completed small_molecule

Poor Quality Sleep

CT.gov ↗
NCT00264329
Transitional Case Management Study

Phase 3 completed other

Substance-Related Disorders

CT.gov ↗
NCT00270257
Buprenorphine/Naloxone

Phase 3 terminated small_molecule

HIV Infections

CT.gov ↗
NCT00271024
Naltrexone (drug)

Phase 2 completed small_molecule

Smoking

CT.gov ↗
NCT00271219
Methadone

Phase 3 terminated small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00279110
Directly administered antiretroviral therapy (DAART)

Phase 3 completed other

HIV Infections

CT.gov ↗
NCT00288483
Policosanol

Phase 3 terminated small_molecule

Hypercholesterolemia

CT.gov ↗
NCT00291512
Theory-based counseling program

Phase 2 completed other

HIV Infections

CT.gov ↗
NCT00294671
diflunisal

Phase 3 completed small_molecule

Familial Amyloid Polyneuropathy

CT.gov ↗
NCT00297453
Internet-based smoking treatment

Phase 3 completed other

Nicotine Dependence

CT.gov ↗
NCT00297492
Pre-Quit Nicotine Lozenges

Phase 2 completed small_molecule

Smoking Cessation

CT.gov ↗
NCT00297505
Citalopram

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00297700
Active referral

Phase 3 active other

Smoking

CT.gov ↗
NCT00301210
Tramadol

Phase 2 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT00304707
Bupropion

Phase 3 completed small_molecule

Smoking Cessation

CT.gov ↗
NCT00310258
Drug use prevention intervention

Phase 3 completed other

Adolescent Behavior

CT.gov ↗
NCT00314353
Bevacizumab

Phase 2 terminated small_molecule

Colorectal Neoplasms

CT.gov ↗
NCT00318383
NicVAX conjugate vaccine

Phase 2 completed mab

Smoking Cessation

CT.gov ↗
NCT00318409
Bupropion

Phase 2 completed small_molecule

Substance Abuse

CT.gov ↗
NCT00336180
HealthWise South Africa curriculum

Phase 3 completed other

Substance-Related Disorders

CT.gov ↗
NCT00350285
Motivational enhancement therapy

Phase 2 completed other

Cannabis Abuse

CT.gov ↗
NCT00360269
Atomoxetine

Phase 2 completed small_molecule

Marijuana Abuse

CT.gov ↗
NCT00365417
Bevacizumab

Phase 2 completed small_molecule

Breast Cancer

CT.gov ↗
NCT00367380
413ABM

Phase 2 completed other

MALARIA

CT.gov ↗
NCT00373295
Baclofen

Phase 2 completed small_molecule

Marijuana Dependence

CT.gov ↗
NCT00373503
Lofexidine

Phase 2 completed small_molecule

Marijuana Dependence

CT.gov ↗
NCT00373880
Aripiprazole + Cocaine

Phase 2 completed small_molecule

Cocaine Abuse

CT.gov ↗
NCT00374127
Marijuana blunt

Phase 2 completed small_molecule

Marijuana Dependence

CT.gov ↗
NCT00378079
Counseling + Transfer

Phase 3 completed small_molecule

Heroin Addiction

CT.gov ↗
NCT00379444
Standard intervention (counseling + self-help written materials)

Phase 2 completed other

Tobacco Use

CT.gov ↗
NCT00384254
5 A

Phase 2 completed other

Tobacco Use Cessation

CT.gov ↗
NCT00391482
Peer Mentoring Intervention for HCV-Infected IDUs

Phase 3 completed other

Hepatitis C

CT.gov ↗
NCT00403117
Placebo + Inactive Marijuana (0% THC)

Phase 2 completed small_molecule

Marijuana Use

CT.gov ↗
NCT00406484
Standard drug counseling

Phase 2 completed other

Opiate Dependence

CT.gov ↗
NCT00409552
Virtual Reality based distraction

Phase 2 completed other

Pain

CT.gov ↗
NCT00419731
Bupropion

Phase 3 active small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00420771
Gabapentin

Phase 2 completed small_molecule

Benzodiazepine Dependence

CT.gov ↗
NCT00421603
Adderall-XR and Topiramate

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00430573
D-cycloserine

Phase 2 terminated small_molecule

Substance-Related Disorders

CT.gov ↗
NCT00438139
Dronabinol

Phase 2 terminated small_molecule

Marijuana Dependence

CT.gov ↗
NCT00439413
Selegiline Transdermal Patch

Phase 2 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT00442923
Coreg

Phase 2 terminated small_molecule

Anxiety

CT.gov ↗
NCT00459953
Extended treatment

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT00469079
Nicotine gum and lozenge

Phase 2 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT00469885
Nicotine replacement

Phase 2 completed small_molecule

Cardiovascular Disease

CT.gov ↗
NCT00476242
Vivitrol

Phase 3 completed small_molecule

Opioid Dependence

CT.gov ↗
NCT00480441
Dronabinol

Phase 2 terminated small_molecule

Marijuana Dependence

CT.gov ↗
NCT00496990
Enhanced care

Phase 3 completed other

Drug Addiction

CT.gov ↗
NCT00497055
Aripiprazole

Phase 2 completed small_molecule

Substance Abuse

CT.gov ↗
NCT00497068
tobacco abstinent contingent

Phase 3 completed other

Nicotine Dependence

CT.gov ↗
NCT00500877
Mood Management Phone Counseling for Smoking Cessation

Phase 2 completed other

Cigarette Smoking

CT.gov ↗
NCT00503230
Standard Care Intervention (SCI)

Phase 3 completed other

Tobacco Dependence

CT.gov ↗
NCT00507728
Bupropion

Phase 3 active small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT00510016
Clonidine HCL

Phase 3 completed small_molecule

Neonatal Abstinence Syndrome

CT.gov ↗
NCT00520286
Modafinil

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT00547118
Rimonabant

Phase 2 terminated small_molecule

Schizophrenia

CT.gov ↗
NCT00551720
Standard Care

Phase 3 completed other

HIV Infections

CT.gov ↗
NCT00551863
IVPT

Phase 2 completed other

Substance Use Disorders

CT.gov ↗
NCT00553319
Placebo

Phase 3 completed small_molecule

Adult Attention Deficit Hyperactivity Disorder

CT.gov ↗
NCT00567008
Varenicline

Phase 2 terminated small_molecule

Cocaine Dependence

CT.gov ↗
NCT00567840
PA-824

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT00569374
Modafinil

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT00573183
STAGE-12

Phase 3 completed other

Drug Abuse

CT.gov ↗
NCT00574067
Buprenorphine +OTP

Phase 3 completed small_molecule

Heroin Addiction

CT.gov ↗
NCT00578669
Fluoxetine

Phase 3 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT00582491
Modafinil

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00596843
Motivational interviewing

Phase 3 completed other

HIV

CT.gov ↗
NCT00607269
Voucher-Based Reinforcement Therapy

Phase 3 completed other

Substance-related Disorders

CT.gov ↗
NCT00609089
CRAFT-T

Phase 2 active other

Heroin Dependence

CT.gov ↗
NCT00612287
buprenorphine

Phase 2 active small_molecule

Chronic Pain

CT.gov ↗
NCT00613015
Guanfacine

Phase 2 completed small_molecule

Cocaine Related Disorders

CT.gov ↗
NCT00617201
atomoxetine

Phase 2 completed small_molecule

Substance Abuse

CT.gov ↗
NCT00618943
Tobacco Use Cessation

Phase 3 completed other

Tobacco Use Cessation

CT.gov ↗
NCT00626834
Vigabatrin

Phase 3 completed small_molecule

Cocaine Addiction

CT.gov ↗
NCT00632099
Oral micronized progesterone

Phase 3 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00664092
Residential

Phase 2 completed other

Usual Aftercare

CT.gov ↗
NCT00685074
Computer-based Motivational Interviewing

Phase 2 completed other

Substance Abuse

CT.gov ↗
NCT00685451
Cognitive Behavioral Therapy (CBT)

Phase 2 completed other

Stress Disorders, Post Traumatic

CT.gov ↗
NCT00687713
Bupropion

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT00688805
Propranolol

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00709007
Directly administered antiretroviral therapy (DAART)

Phase 3 completed other

HIV Infections

CT.gov ↗
NCT00713063
aerobic exercise

Phase 2 completed other

Nicotine Dependence

CT.gov ↗
NCT00719095
buprenorphine taper followed by naltrexone maintenance

Phase 2 completed small_molecule

Prescription Opioid Dependence

CT.gov ↗
NCT00731055
Varenicline

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT00732901
Escitalopram

Phase 3 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00733993
Caffeine 150 MG

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00743119
Placebo capsules

Phase 2 completed small_molecule

Pain Threshold

CT.gov ↗
NCT00743145
Inactive Marijuana (0% THC)

Phase 2 completed small_molecule

Marijuana Smoking

CT.gov ↗
NCT00759473
D-Cycloserine (DCS)

Phase 2 completed small_molecule

Cocaine Use Disorders

CT.gov ↗
NCT00773357
Guanfacine

Phase 2 completed small_molecule

Smoking

CT.gov ↗
NCT00777062
VIVITROL (Naltrexone extended-release injectable suspension)

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00780260
strengths-based case management

Phase 3 completed other

HIV

CT.gov ↗
NCT00780338
Assets Getting To Outcomes

Phase 2 completed other

Substance Abuse

CT.gov ↗
NCT00781898
Depot naltrexone

Phase 3 completed small_molecule

Opiate Addiction

CT.gov ↗
NCT00809835
Galantamine

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00830362
Propranolol

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00838773
YMSM

Phase 2 completed other

Behavior

CT.gov ↗
NCT00838981
Modafinil

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00840658
Interactive injection and sexual risk intervention

Phase 2 completed other

HIV

CT.gov ↗
NCT00864383
REMoxTB

Phase 3 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT00876941
Standard Brief Intervention

Phase 3 completed other

Drug Usage

CT.gov ↗
NCT00880997
Doxazosin

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00884897
Oxytocin

Phase 2 completed small_molecule

Social Cognition

CT.gov ↗
NCT00893074
Dronabinol 30mg/day

Phase 2 completed small_molecule

Marijuana Abuse

CT.gov ↗
NCT00895557
chantix

Phase 2 terminated small_molecule

Varenicline and the Blunting of Cocaine Cues

CT.gov ↗
NCT00913484
Disulfiram

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT00934141
Learning Session

Phase 3 completed other

Addiction

CT.gov ↗
NCT00944021
PA-824

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT00967005
N Acetyl Cysteine

Phase 2 completed small_molecule

Gambling

CT.gov ↗
NCT00980044
Tramadol

Phase 3 completed small_molecule

Substance Withdrawal Syndrome

CT.gov ↗
NCT00993070
Capsaicin

Phase 3 completed small_molecule

Diabetic Polyneuropathy

CT.gov ↗
NCT00994448
Bupropion SR 150mg tabs

Phase 2 completed small_molecule

Adolescent Methamphetamine Abuse

CT.gov ↗
NCT01001520
Tolcapone

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT01003496
Treatment as Usual (TAU)

Phase 3 completed other

Drug Addiction

CT.gov ↗
NCT01005810
N-Acetylcysteine

Phase 3 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01018654
Standard Cognitive Behavioral Treatment

Phase 2 completed other

Substance-Related Disorders

CT.gov ↗
NCT01020019
Dronabinol

Phase 3 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01028131
Computer-delivered brief intervention (5As)

Phase 2 completed other

Smoking

CT.gov ↗
NCT01048359
Brief advice

Phase 3 completed other

Drug Abuse

CT.gov ↗
NCT01048905
L-Glutamine

Phase 2 completed small_molecule

Pulmonary Hypertension

CT.gov ↗
NCT01050569
Nicotine Patch

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT01065493
QuitAdvisorMD Software Algorithm

Phase 2 active other

Smoking

CT.gov ↗
NCT01082341
Immunization with P. vivax irradiated sporozoites

Phase 2 completed mab

Malaria

CT.gov ↗
NCT01100853
811095

Phase 3 completed small_molecule

Amphetamine Dependence

CT.gov ↗
NCT01101815
Oral Naltrexone

Phase 2 completed small_molecule

HIV

CT.gov ↗
NCT01109563
Marijuana Check-Ins

Phase 3 completed other

Cannabis Use Disorder

CT.gov ↗
NCT01110434
Topiramate

Phase 2 completed small_molecule

Cannabis Abuse

CT.gov ↗
NCT01114308
Probuphine (buprenorphine implant)

Phase 3 completed small_molecule

Opioid Dependency

CT.gov ↗
NCT01124591
Brief motivational intervention

Phase 2 completed other

Substance Abuse Detection

CT.gov ↗
NCT01131273
methadone

Phase 3 completed small_molecule

HIV

CT.gov ↗
NCT01143792
Community Reinforcement Approach (CRA) + HIV prevention

Phase 2 completed other

Substance Abuse

CT.gov ↗
NCT01143857
Varenicline

Phase 2 terminated small_molecule

Cocaine Dependence

CT.gov ↗
NCT01145183
Doxazosin

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01151813
Varenicline

Phase 2 completed small_molecule

Alcohol Dependence

CT.gov ↗
NCT01153594
Recovery Management Checkups (RMC)

Phase 3 completed other

Substance Use Disorders

CT.gov ↗
NCT01159535
Mindfulness Based Relapse Prevention

Phase 2 completed other

Substance Use Disorders

CT.gov ↗
NCT01162239
Varenicline

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT01163864
affect regulation training

Phase 2 completed other

Smoking Cessation

CT.gov ↗
NCT01176591
Placebo session 1, Aprepitant session 2

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01178138
Prazosin

Phase 2 completed small_molecule

Continuous Methamphetamine Abuse

CT.gov ↗
NCT01188967
GSK598809

Phase 2 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT01189305
Behavioral Couples Therapy

Phase 2 completed other

Drug Abuse

CT.gov ↗
NCT01196247
SU2C-001

Phase 2 completed small_molecule

Previously Treated Metastatic Pancreatic Cancer

CT.gov ↗
NCT01199380
Transdermal Nicotine Patch

Phase 2 completed small_molecule

Cigarette Smoking

CT.gov ↗
NCT01206036
Docetaxel

Phase 2 completed small_molecule

Prostatic Neoplasms

CT.gov ↗
NCT01213524
42 mg transdermal nicotine replacement

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT01215110
TMC207

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT01215851
PA-824

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT01222936
LBH581

Phase 2 completed small_molecule

Small Cell Lung Carcinoma

CT.gov ↗
NCT01246401
Extended-Release Naltrexone

Phase 2 completed small_molecule

HIV

CT.gov ↗
NCT01266109
Contingency Management-Family Engagement (CM-FAM)

Phase 2 completed other

Adolescent Substance Use

CT.gov ↗
NCT01271413
Computerized cognitively stimulating activities

Phase 2 completed other

Substance Use Disorders

CT.gov ↗
NCT01281202
Vigabatrin

Phase 3 completed small_molecule

Cocaine Addiction

CT.gov ↗
NCT01292577
CET/PT

Phase 2 completed other

Schizophrenia

CT.gov ↗
NCT01314001
Varenicline

Phase 3 completed small_molecule

Nicotine Addiction

CT.gov ↗
NCT01315184
Recovery Line Support System

Phase 2 completed other

Opioid-Related Disorders

CT.gov ↗
NCT01326767
Paclitaxel dosing according to SmPC

Phase 3 completed small_molecule

Carcinoma, Non-Small-Cell Lung

CT.gov ↗
NCT01327586
ATM

Phase 2 completed other

Dual Diagnosis

CT.gov ↗
NCT01330030
Selegiline

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT01347762
Nabilone

Phase 3 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01360450
Clonidine HCL

Phase 3 completed small_molecule

Neonatal Abstinence Syndrome

CT.gov ↗
NCT01360463
Behavioral Drug and Risk Counseling (BDRC)

Phase 2 completed other

HIV Risk Behaviors

CT.gov ↗
NCT01371851
Doxazosin extended release

Phase 2 completed small_molecule

Methamphetamine or Cocaine Dependence

CT.gov ↗
NCT01372033
Cognitive Behavioral Therapy

Phase 3 completed other

Substance Abuse

CT.gov ↗
NCT01372046
Booster Sessions

Phase 3 completed other

Skill Development of Staff

CT.gov ↗
NCT01377662
OND-PR002 and MPh-IR

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT01380613
Workshop

Phase 2 completed other

HIV

CT.gov ↗
NCT01381133
Chestnut Bloomington Outpatient (CBOP)

Phase 3 completed other

Substance Abuse

CT.gov ↗
NCT01389167
Vivitrol

Phase 3 completed small_molecule

Opiate Dependence

CT.gov ↗
NCT01389180
Behavioral Drug and HIV Risk Reduction Counseling

Phase 3 completed other

Opiate Dependence

CT.gov ↗
NCT01394185
Dronabinol 120mg/day

Phase 2 completed small_molecule

Marijuana Smoking

CT.gov ↗
NCT01395797
PIO

Phase 2 terminated small_molecule

Heroin Dependence

CT.gov ↗
NCT01402492
Buprenorphine + Naltrexone

Phase 3 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01406223
Varenicline

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT01413529
HEART to HAART

Phase 2 completed other

HIV

CT.gov ↗
NCT01419899
Brief motivational intervention

Phase 3 completed other

Drug Use

CT.gov ↗
NCT01442597
Standard Treatment As Usual (TAU)

Phase 2 completed other

Substance Abuse

CT.gov ↗
NCT01454921
Evolution: Young Women Taking Charge and Growing Stronger

Phase 2 completed other

HIV

CT.gov ↗
NCT01457391
Cognitive Behavioral Therapy

Phase 3 completed other

Stress Disorders, Post-Traumatic

CT.gov ↗
NCT01461915
Nab paclitaxel

Phase 2 terminated small_molecule

Metastatic Pancreatic Cancer

CT.gov ↗
NCT01465490
Monitoring and Feedback Intervention

Phase 2 completed other

Substance Abuse

CT.gov ↗
NCT01465555
Cognitive Behavioral Intervention

Phase 2 completed other

Substance Abuse

CT.gov ↗
NCT01480232
EVP-6124

Phase 2 terminated small_molecule

Nicotine Dependence

CT.gov ↗
NCT01486810
Lisdexamfetamine

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01495195
High-dose donepezil

Phase 2 completed small_molecule

Cocaine Use Disorders

CT.gov ↗
NCT01498419
Moxifloxacin (M)

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT01524627
Varenicline

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT01535573
Citalopram

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01535937
Ketamine

Phase 2 terminated small_molecule

Cocaine Dependence

CT.gov ↗
NCT01556425
Vivitrol

Phase 3 completed small_molecule

Opioid Dependence

CT.gov ↗
NCT01557569
Atomoxetine

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT01571167
Placebo

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT01586676
SAU

Phase 3 completed other

Signs and Symptoms

CT.gov ↗
NCT01611948
Aprepitant

Phase 2 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01618656
PF-04457845

Phase 2 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01622855
PPRS

Phase 2 completed other

Drug Use

CT.gov ↗
NCT01641159
Buspirone

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01650675
R01DA029050

Phase 2 completed other

Drug Abuse

CT.gov ↗
NCT01669538
Galantamine

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT01675661
N-Acetylcysteine

Phase 3 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01685073
Zolpidem extended-release

Phase 3 completed small_molecule

Drug Addiction

CT.gov ↗
NCT01691534
TMC207 (J)

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT01697709
Quetiapine

Phase 2 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01704196
Nepicastat

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01710137
Varenicline

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT01723384
Intermittent Oral Naltrexone

Phase 2 completed small_molecule

Methamphetamine

CT.gov ↗
NCT01730846
Doxazosin 4mg/day

Phase 2 completed small_molecule

Smoking

CT.gov ↗
NCT01740414
MN-166 (50 mg) First

Phase 2 completed small_molecule

Opioid Abuse

CT.gov ↗
NCT01741532
Deferiprone oral solution

Phase 3 completed small_molecule

Pantothenate Kinase-Associated Neurodegeneration

CT.gov ↗
NCT01747850
Sativex

Phase 2 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT01757418
Immune Globulin Intravenous (IVIG)

Phase 2 completed small_molecule

Sickle Cell Disease

CT.gov ↗
NCT01768767
Placebo

Phase 2 terminated small_molecule

Bipolar Depression

CT.gov ↗
NCT01772251
Oshadi Icp

Phase 2 completed small_molecule

Diabetes Mellitus, Insulin-Dependent, 1

CT.gov ↗
NCT01778010
Modafinil 0 mg

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01784809
Multimedia WORTH

Phase 2 completed other

HIV

CT.gov ↗
NCT01803763
Omalizumab (Xolair)

Phase 3 completed small_molecule

Chronic Urticaria

CT.gov ↗
NCT01806779
Chantix

Phase 2 terminated small_molecule

Nicotine Dependence

CT.gov ↗
NCT01823250
Family Therapy based on Structural Family Therapy

Phase 2 completed other

Substance Use Disorders

CT.gov ↗
NCT01860807
Ibudilast

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT01863186
Lofexidine HCl

Phase 3 completed small_molecule

Opioid Dependence

CT.gov ↗
NCT01882361
injectable naltrexone

Phase 3 completed small_molecule

Opiate Dependence

CT.gov ↗
NCT01888835
Mirtazapine

Phase 2 completed small_molecule

Amphetamine-Related Disorders

CT.gov ↗
NCT01895036
Naltrexone

Phase 2 completed small_molecule

Stable Opioid Dependence

CT.gov ↗
NCT01895270
Isradipine

Phase 2 completed small_molecule

Opioid Dependence

CT.gov ↗
NCT01895361
SelG1

Phase 2 completed small_molecule

Sickle Cell Disease

CT.gov ↗
NCT01904526
Guanfacine

Phase 2 completed small_molecule

Smoking

CT.gov ↗
NCT01908062
Extended Release Naltrexone

Phase 3 completed small_molecule

Opioid Use Disorder

CT.gov ↗
NCT01938664
Candesartan with CBT

Phase 2 terminated small_molecule

Cocaine Dependence

CT.gov ↗
NCT01948674
Computerized tasks

Phase 2 completed other

Substance Use Disorders

CT.gov ↗
NCT01972464
Progesterone

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT01986075
Mixed-Amphetamine Salts- Extended Release (MAS-ER)

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT01992146
Target-controlled naloxone-infusion

Phase 2 completed small_molecule

Central Nervous System Sensitization

CT.gov ↗
NCT02013323
GDCRI/ACM/PG/PhD/10/2013-14

Phase 2 completed small_molecule

Chronic Periodontitis

CT.gov ↗
NCT02016378
Bias retraining

Phase 3 completed other

Alcohol Use Disorder

CT.gov ↗
NCT02019459
Very low nicotine content cigarettes

Phase 2 completed small_molecule

Tobacco Dependence

CT.gov ↗
NCT02051309
Guanfacine

Phase 2 completed small_molecule

Smoking Cessation

CT.gov ↗
NCT02067156
G-202

Phase 2 completed small_molecule

Glioblastoma Multiforme

CT.gov ↗
NCT02080832
Citalopram

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT02083068
Vaccine PvCS N+C+R

Phase 2 completed mab

Malaria

CT.gov ↗
NCT02084316
One4All

Phase 3 completed other

HIV

CT.gov ↗
NCT02085265
Perindopril

Phase 2 terminated small_molecule

Alzheimer's Disease

CT.gov ↗
NCT02090283
SD-101 dermal cream (6%)

Phase 2 terminated small_molecule

Epidermolysis Bullosa

CT.gov ↗
NCT02111798
Placebo

Phase 3 completed small_molecule

Substance Abuse

CT.gov ↗
NCT02125539
Navigating my Journey program

Phase 2 completed other

Substance-Related Disorders

CT.gov ↗
NCT02193776
PA-824

Phase 2 completed small_molecule

Tuberculosis

CT.gov ↗
NCT02210195
Aprepitant

Phase 2 completed small_molecule

Cannabis Dependence

CT.gov ↗
NCT02232776
Losartan

Phase 3 completed small_molecule

Glomerulonephritis, IGA

CT.gov ↗
NCT02250664
Very low nicotine content cigarettes

Phase 2 completed other

Tobacco Use Disorder

CT.gov ↗
NCT02279875
Linezolid

Phase 2 completed small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT02302170
H. pylori vaccine

Phase 3 completed mab

H. Pylori Infection

CT.gov ↗
NCT02312908
Clonazepam

Phase 2 completed small_molecule

REM Sleep Behavior Disorder

CT.gov ↗
NCT02342886
Moxifloxacin

Phase 3 completed small_molecule

Tuberculosis, Pulmonary, Drug Sensitive

CT.gov ↗
NCT02344225
Caffeine citrate

Phase 2 completed small_molecule

Retinopathy of Prematurity

CT.gov ↗
NCT02348359
X-82

Phase 2 terminated small_molecule

Age-Related Macular Degeneration (AMD)

CT.gov ↗
NCT02355080
On-site bundled rapid HIV/HCV testing

Phase 3 completed other

Substance-related Disorders

CT.gov ↗
NCT02363998
Lofexidine

Phase 3 completed small_molecule

Opioid Withdrawal

CT.gov ↗
NCT02412631
lorcaserin

Phase 3 terminated small_molecule

Obesity

CT.gov ↗
NCT02432066
GTS-21

Phase 2 terminated small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT02437344
CI-581aa

Phase 2 completed small_molecule

Opioid Dependence

CT.gov ↗
NCT02460692
Placebos

Phase 2 completed small_molecule

Cannabis

CT.gov ↗
NCT02501265
Varenicline Adaptive Protocol

Phase 2 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT02541409
Sofosbuvir

Phase 2 completed small_molecule

Hepatitis C, Chronic

CT.gov ↗
NCT02543944
Gabapentin

Phase 3 completed small_molecule

Drug Dependence

CT.gov ↗
NCT02560324
Ramelteon

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT02590393
E-cigarettes

Phase 2 completed other

Nicotine Dependence

CT.gov ↗
NCT02597257
Lidocaine HCl

Phase 2 active small_molecule

Postherpetic Neuralgia

CT.gov ↗
NCT02643056
Panitumumab

Phase 2 completed small_molecule

Advanced Head and Neck Squamous Cancer

CT.gov ↗
NCT02698215
Varenicline

Phase 3 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT02705508
Gemcitabine

Phase 2 active small_molecule

Treatment Refusal

CT.gov ↗
NCT02707055
PF-05190457

Phase 2 terminated small_molecule

Alcoholism

CT.gov ↗
NCT02737358
N-acetylcysteine (NAC)

Phase 2 completed small_molecule

Nicotine Dependence

CT.gov ↗
NCT02800928
CERC-501

Phase 2 completed small_molecule

Smoking

CT.gov ↗
NCT02803229
Adderall-XR

Phase 3 completed small_molecule

Cannabis Use Disorder

CT.gov ↗
NCT02815033
Enzalutamide

Phase 2 completed small_molecule

Prostate Cancer Metastatic

CT.gov ↗
NCT02856854
EMB-001

Phase 2 completed small_molecule

Cocaine Use Disorder

CT.gov ↗
NCT02862210
Lithium Carbonate

Phase 2 completed small_molecule

Frontotemporal Dementia (FTD)

CT.gov ↗
NCT02867124
XR-NTX

Phase 3 completed small_molecule

Opiate Addiction

CT.gov ↗
NCT02870218
Smoking research cigarettes with e-cigarette

Phase 2 completed small_molecule

Nicotine Addiction

CT.gov ↗
NCT02913924
Clonazepam

Phase 2 completed small_molecule

Cannabis Use Disorder

CT.gov ↗
NCT02919293
Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)

Phase 2 active mab

Meningitis

CT.gov ↗
NCT02957760
Hydroxycarbamid

Phase 2 active small_molecule

Central Retinal Vein Occlusion, Non-Ischemic

CT.gov ↗
NCT02964065
Live-Attenuated influenza Vaccine(LAIV)

Phase 3 completed mab

Influenza

CT.gov ↗
NCT02969083
Gemcitabine/Cisplatin

Phase 2 active small_molecule

Upper Tract Urothelial Carcinoma

CT.gov ↗
NCT02971605
Psilocybin

Phase 2 completed small_molecule

Healthy

CT.gov ↗
NCT02994875
N-Acetylcysteine

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT03007394
Lorcaserin

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT03069768
Chantix

Phase 2 terminated small_molecule

Nicotine Dependence

CT.gov ↗
NCT03086486
Pretomanid

Phase 3 completed small_molecule

Tuberculosis, Pulmonary

CT.gov ↗
NCT03098563
Blinded study medication

Phase 2 completed small_molecule

Knee Osteoarthritis

CT.gov ↗
NCT03144232
Active rTMS

Phase 2 completed other

Cannabis Use Disorder

CT.gov ↗
NCT03150173
Buprenorphine

Phase 2 completed small_molecule

Opiate Addiction

CT.gov ↗
NCT03202693
PA-824

Phase 2 completed small_molecule

Tuberculosis

CT.gov ↗
NCT03232346
Vivitrol

Phase 3 completed small_molecule

Opioid-use Disorder

CT.gov ↗
NCT03238859
Real cTBS

Phase 2 completed other

Cocaine Dependence

CT.gov ↗
NCT03251326
Nabilone

Phase 2 terminated small_molecule

Cannabis

CT.gov ↗
NCT03253926
Lorcaserin

Phase 2 completed small_molecule

Cannabis Use

CT.gov ↗
NCT03274167
Gabapentin 300mg

Phase 3 completed small_molecule

Alcohol Drinking

CT.gov ↗
NCT03291847
Buprenorphine Naloxone

Phase 2 completed small_molecule

Maternal Opioid Use Disorder

CT.gov ↗
NCT03336866
Placebo

Phase 2 completed small_molecule

Methamphetamine Dependence

CT.gov ↗
NCT03338621
Pretomanid

Phase 3 completed small_molecule

Tuberculosis, Pulmonary

CT.gov ↗
NCT03344419
CI-581a

Phase 3 on hold small_molecule

Cocaine Use Disorder

CT.gov ↗
NCT03430544
Cariprazine Oral Capsule [Vraylar]

Phase 2 terminated small_molecule

Cocaine Use Disorder

CT.gov ↗
NCT03512418
Truvada

Phase 3 completed small_molecule

HIV Infections

CT.gov ↗
NCT03537495
Linezolid

Phase 2 completed small_molecule

Tuberculosis, Meningeal

CT.gov ↗
NCT03576417
Cisplatin

Phase 3 active small_molecule

Squamous Cell Carcinoma of Head and Neck

CT.gov ↗
NCT03612960
Very low nicotine content cigarettes

Phase 2 completed small_molecule

Tobacco Dependence

CT.gov ↗
NCT03634007
LX1001

Phase 2 completed mab

Alzheimer Disease

CT.gov ↗
NCT03664921
Omnitram Oral Tablet

Phase 2 completed small_molecule

Diabetic Neuropathies

CT.gov ↗
NCT03680287
Within-Subject test of blinded study medication

Phase 2 completed small_molecule

Low Back Pain, Recurrent

CT.gov ↗
NCT03717272
AEF0117

Phase 2 completed small_molecule

Marijuana Abuse

CT.gov ↗
NCT03718065
Lofexidine

Phase 2 completed small_molecule

Opioid-use Disorder

CT.gov ↗
NCT03729869
Progesterone

Phase 2 completed small_molecule

Cannabis Use

CT.gov ↗
NCT03766971
Cannabis

Phase 2 active small_molecule

Cannabis Use

CT.gov ↗
NCT03769025
Suboxone Remote Observed Dosing

Phase 2 completed other

Opioid-use Disorder

CT.gov ↗
NCT03772665
Emixustat

Phase 3 completed small_molecule

Stargardt Disease

CT.gov ↗
NCT03787628
Cannabidiol (CBD) 600 mg

Phase 2 completed small_molecule

Opioid-use Disorder

CT.gov ↗
NCT03860077
Very Low Nicotine Content Cigarettes

Phase 2 completed small_molecule

Nicotine Dependence, Cigarettes, Uncomplicated

CT.gov ↗
NCT03867253
ORY-2001 Low dose

Phase 2 completed small_molecule

Mild to Moderate Alzheimer's Disease

CT.gov ↗
NCT03897439
Nicotine Patch

Phase 3 completed small_molecule

Smoking Cessation

CT.gov ↗
NCT03912194
cognitive-behavioral withdrawal regulation strategies

Phase 3 active other

Tobacco Dependence

CT.gov ↗
NCT03918850
Buprenorphine Injection

Phase 3 completed small_molecule

Opioid-Related Disorders

CT.gov ↗
NCT03921151
Mirtazapine 15 MG Oral Tablet

Phase 2 completed small_molecule

Cocaine Dependence

CT.gov ↗
NCT03972137
Transdermal Nicotine patch

Phase 2 completed small_molecule

Tobacco Smoking

CT.gov ↗
NCT03980184
Guanfacine

Phase 2 completed small_molecule

Substance Use Disorders

CT.gov ↗
NCT03981523
Benznidazole

Phase 2 completed small_molecule

Trypanosoma Cruzi Infection

CT.gov ↗
NCT04033237
Very low nicotine content cigarettes

Phase 2 completed other

Tobacco Use Disorder

CT.gov ↗
NCT04035603
D-Cycloserine

Phase 2 terminated small_molecule

Smoking Cessation

CT.gov ↗
NCT04036968
Within-subject test of blinded study medications

Phase 2 completed small_molecule

Pain

CT.gov ↗
NCT04038515
Nicotine 0 mg/mL

Phase 2 completed small_molecule

Nicotine

CT.gov ↗
NCT04050176
Hypnotic Medication Open-Label Taper

Phase 3 active other

Hypnotic Dependence Among Those With Insomnia

CT.gov ↗
NCT04081077
Bedaquiline

Phase 3 active small_molecule

Multi-drug Resistant Tuberculosis

CT.gov ↗
NCT04090879
CHRMS19-0129

Phase 2 completed other

Tobacco Use Disorder

CT.gov ↗
NCT04092101
Cigarettes with varying nicotine content

Phase 2 completed other

Tobacco Use Disorder

CT.gov ↗
NCT04100759
Sildenafil 50 mg Oral Tablet

Phase 2 completed small_molecule

Erectile Dysfunction

CT.gov ↗
NCT04109118
BZD discontinuation protocol

Phase 2 completed small_molecule

Substance Use Disorders

CT.gov ↗
NCT04128059
BVRS-GamVac-Combi

Phase 2 active small_molecule

MERS (Middle East Respiratory Syndrome)

CT.gov ↗
NCT04155632
N-acetylcysteine

Phase 2 completed small_molecule

Cocaine-Related Disorders

CT.gov ↗
NCT04177706
Ketamine Hydrochloride

Phase 2 completed small_molecule

Depression

CT.gov ↗
NCT04199728
Liraglutide Pen Injector

Phase 2 completed small_molecule

Opiate Substitution Treatment

CT.gov ↗
NCT04225598
CAM2038

Phase 2 completed small_molecule

Opioid-use Disorder

CT.gov ↗
NCT04268966
Brincidofovir

Phase 2 terminated small_molecule

Ebola Virus Disease

CT.gov ↗
NCT04316559
TRV734

Phase 2 completed small_molecule

Opioid-Use Disorder

CT.gov ↗
NCT04345718
Extended Release Buprenorphine

Phase 3 completed small_molecule

Substance Use Disorder

CT.gov ↗
NCT04347486
Sugammadex Injection 2mg/kg

Phase 2 completed small_molecule

Anesthesia, General

CT.gov ↗
NCT04381468
Pepinemab

Phase 2 completed small_molecule

Alzheimer Disease

CT.gov ↗
NCT04464980
SL-BUP

Phase 2 active small_molecule

Opioid Use Disorder (OUD)

CT.gov ↗
NCT04501874
EMB-001

Phase 2 completed small_molecule

Cocaine Use Disorder

CT.gov ↗
NCT04516057
Nabilone

Phase 3 active small_molecule

Alzheimer Disease

CT.gov ↗
NCT04556552
Oxygen (15-O) Water

Phase 3 completed small_molecule

Substance-Related Disorders

CT.gov ↗
NCT04596644
Active Cannabis

Phase 2 on hold small_molecule

Cannabis

CT.gov ↗
NCT04619862
Gabapentin

Phase 2 active small_molecule

Pain

CT.gov ↗
NCT04642924
SGM-101

Phase 3 active small_molecule

Rectal Cancer

CT.gov ↗
NCT04677114
Buprenorphine and Outpatient Parenteral Antibiotic Therapy

Phase 2 completed small_molecule

Drug Use

CT.gov ↗
NCT04739917
Vaccine PvCS N+C+R 150 mcg

Phase 2 active mab

Malaria, Vivax

CT.gov ↗
NCT04760613
Cannabidiol

Phase 2 completed small_molecule

Radiculopathy

CT.gov ↗
NCT04804241
Senicapoc

Phase 2 active small_molecule

Mild Cognitive Impairment

CT.gov ↗
NCT04818086
Lemborexant

Phase 2 completed small_molecule

Drug Interaction

CT.gov ↗
NCT04839198
Nicotine Patch

Phase 3 completed small_molecule

Smoking Cessation

CT.gov ↗
NCT04843046
Pioglitazone

Phase 2 completed small_molecule

Cocaine Use Disorder

CT.gov ↗
NCT04880863
NAP (Naptumomab estafenatox)

Phase 2 completed small_molecule

Non-small Cell Lung Cancer

CT.gov ↗
NCT04988477
Study 3: Chronic care management

Phase 2 completed other

Smoking, Tobacco

CT.gov ↗
NCT04991974
Buprenorphine

Phase 3 active small_molecule

Opioid-use Disorder

CT.gov ↗
NCT05030272
Nicotine Patch

Phase 2 completed small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT05063500
bicyclol, 25mg/ tablet

Phase 3 active small_molecule

Drug-Induced Acute Liver Injury

CT.gov ↗
NCT05109169
FINGER 2.0 multidomain lifestyle-based intervention

Phase 2 active other

Cognitive Decline

CT.gov ↗
NCT05152134
Empowered Relief On-Demand

Phase 3 completed other

Chronic Pain

CT.gov ↗
NCT05159947
SPT-07A injection

Phase 3 active small_molecule

Stroke, Acute

CT.gov ↗
NCT05224050
Heart Rate Variability Biofeedback

Phase 2 completed mab

Tobacco Smoking

CT.gov ↗
NCT05339256
Buprenorphine SL

Phase 2 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT05378399
Descovy or Truvada

Phase 3 completed small_molecule

HIV Infections

CT.gov ↗
NCT05385783
CYB003

Phase 2 completed small_molecule

Major Depressive Disorder

CT.gov ↗
NCT05452772
Psilocybin

Phase 2 active small_molecule

Tobacco Use Disorder

CT.gov ↗
NCT05459402
Methadone (100% dose)

Phase 3 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT05468073
Proleukin

Phase 2 active small_molecule

Alzheimer Disease

CT.gov ↗
NCT05555706
B013+Nab-Paclitaxel

Phase 3 completed small_molecule

Triple Negative Breast Cancer (TNBC)

CT.gov ↗
NCT05558358
18-0254

Phase 2 active other

Methamphetamine Use Disorder

CT.gov ↗
NCT05613166
Everolimus

Phase 2 active small_molecule

Epilepsy

CT.gov ↗
NCT05641766
THC

Phase 2 active small_molecule

THC

CT.gov ↗
NCT05651022
Decoy20

Phase 2 active small_molecule

Solid Tumor, Adult

CT.gov ↗
NCT05662020
KLWS-V502-04

Phase 3 active mab

Human Papillomavirus Infection

CT.gov ↗
NCT05668403
B007

Phase 3 active small_molecule

Primary Membranous Nephropathy

CT.gov ↗
NCT05694728
KLWS-V502-02

Phase 2 completed mab

Human Papilloma Virus Infection

CT.gov ↗
NCT05712707
BXCL501 (180 micrograms)

Phase 2 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT05742698
Nabilone

Phase 2 active small_molecule

Frontotemporal Dementia

CT.gov ↗
NCT05766631
Methadone Treatment-As-Usual

Phase 3 active small_molecule

Opioid Use

CT.gov ↗
NCT05886582
Rotigotine Transdermal System [Neupro]

Phase 2 active small_molecule

Substance-Related Disorders

CT.gov ↗
NCT05946551
Cetirizine

Phase 3 terminated small_molecule

COVID-19

CT.gov ↗
NCT05971602
Gates MRI-TBD06-201

Phase 2 terminated small_molecule

Pulmonary Tuberculosis

CT.gov ↗
NCT05976646
Placebo

Phase 2 completed small_molecule

Addiction

CT.gov ↗
NCT06032559
MORE

Phase 3 active other

Opioid Use

CT.gov ↗
NCT06033599
MORE and MI and NRT

Phase 3 active other

Polysubstance Abuse

CT.gov ↗
NCT06045793
TNX-1300 (Injection)

Phase 2 terminated small_molecule

Cocaine Use

CT.gov ↗
NCT06047834
Standard of Care with Lofexidine

Phase 2 active small_molecule

Opioid Withdrawal (Disorder)

CT.gov ↗
NCT06107062
Cannabidiol - fsCBD

Phase 2 active small_molecule

Cannabis Use Disorder

CT.gov ↗
NCT06148311
Matching placebo

Phase 2 active small_molecule

Familial Dysautonomia

CT.gov ↗
NCT06233799
extended-release naltrexone (XR-NTX)

Phase 3 active small_molecule

Methamphetamine-dependence

CT.gov ↗
NCT06324318
Parenting in 2 Worlds (P2W)

Phase 2 active other

Parenting

CT.gov ↗
NCT06351540
Cannabis

Phase 2 active small_molecule

Cannabis Use

CT.gov ↗
NCT06401538
BMB-101

Phase 2 active small_molecule

Absence Epilepsy

CT.gov ↗
NCT06434610
B013

Phase 2 active small_molecule

Platinum-resistant Recurrent Ovarian Cancer

CT.gov ↗
NCT06447597
B007

Phase 3 active small_molecule

Generalized Myasthenia Gravis

CT.gov ↗
NCT06470191
B007

Phase 3 active small_molecule

Primary Membranous Nephropathy

CT.gov ↗
NCT06481163
Telacebec

Phase 2 active small_molecule

Buruli Ulcer

CT.gov ↗
NCT06548490
Semaglutide Pen Injector

Phase 2 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT06609369
Varenicline

Phase 2 active small_molecule

Tobacco Use

CT.gov ↗
NCT06667726
Fluorodopa F 18

Phase 2 active small_molecule

Malignant Brain Neoplasm

CT.gov ↗
NCT06721494
Methamphetamine

Phase 2 active small_molecule

Methamphetamine Intoxication

CT.gov ↗
NCT06757140
Alprazolam

Phase 2 active small_molecule

Drug Interactions

CT.gov ↗
NCT06796062
Psilocybin

Phase 2 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT06845878
chatbot

Phase 2 active other

Opiate-Related Disorders

CT.gov ↗
NCT06938347
Agitated Saline SoC

Phase 3 active small_molecule

Right-To-Left Shunt

CT.gov ↗
NCT06940674
Cannabidiol

Phase 3 active small_molecule

Opioid Use Disorder (OUD)

CT.gov ↗
NCT06981195
Placebo

Phase 2 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT07075081
Ceremony

Phase 2 active other

Substance Use

CT.gov ↗
NCT07148206
Dronabinol Capsules

Phase 3 active small_molecule

Opioid Use Disorder

CT.gov ↗
NCT07225777
Dronabinol

Phase 2 active small_molecule

Cannabis Use Disorder

CT.gov ↗
NCT07227948
Semaglutide

Phase 2 active small_molecule

Cocaine Use Disorder

CT.gov ↗
NCT07266324
BMB-101

Phase 2 active small_molecule

Prader-Willi Syndrome

CT.gov ↗
NCT07373301
PvCS/Montanide ISA-51 VG Vaccine

Phase 2 active mab

Plasmodium Vivax Malaria

CT.gov ↗
NCT07398404
Naltrexone hydrochloride

Phase 2 active small_molecule

Obesity

CT.gov ↗
NCT07468552
Tirzepatide

Phase 2 active small_molecule

Cannabis Use Disorder

CT.gov ↗
NCT07510048
Standard of care and PrEP Choice at Enrollment

Phase 2 active other

HIV

CT.gov ↗
NCT07602699
Tirzepatide

Phase 2 active small_molecule

Smoking Cessation

CT.gov ↗